These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
439 related articles for article (PubMed ID: 26662072)
1. Prognostic value of PET/CT with (18)F-fluoroazomycin arabinoside for patients with head and neck squamous cell carcinomas receiving chemoradiotherapy. Saga T; Inubushi M; Koizumi M; Yoshikawa K; Zhang MR; Obata T; Tanimoto K; Harada R; Uno T; Fujibayashi Y Ann Nucl Med; 2016 Apr; 30(3):217-24. PubMed ID: 26662072 [TBL] [Abstract][Full Text] [Related]
2. Prognostic value of (18) F-fluoroazomycin arabinoside PET/CT in patients with advanced non-small-cell lung cancer. Saga T; Inubushi M; Koizumi M; Yoshikawa K; Zhang MR; Tanimoto K; Horiike A; Yanagitani N; Ohyanagi F; Nishio M Cancer Sci; 2015 Nov; 106(11):1554-60. PubMed ID: 26292100 [TBL] [Abstract][Full Text] [Related]
3. FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial. Mortensen LS; Johansen J; Kallehauge J; Primdahl H; Busk M; Lassen P; Alsner J; Sørensen BS; Toustrup K; Jakobsen S; Petersen J; Petersen H; Theil J; Nordsmark M; Overgaard J Radiother Oncol; 2012 Oct; 105(1):14-20. PubMed ID: 23083497 [TBL] [Abstract][Full Text] [Related]
4. Dynamics of tumor hypoxia assessed by 18F-FAZA PET/CT in head and neck and lung cancer patients during chemoradiation: possible implications for radiotherapy treatment planning strategies. Bollineni VR; Koole MJ; Pruim J; Brouwer CL; Wiegman EM; Groen HJ; Vlasman R; Halmos GB; Oosting SF; Langendijk JA; Widder J; Steenbakkers RJ Radiother Oncol; 2014 Nov; 113(2):198-203. PubMed ID: 25434768 [TBL] [Abstract][Full Text] [Related]
5. A prospective clinical study of ¹⁸F-FAZA PET-CT hypoxia imaging in head and neck squamous cell carcinoma before and during radiation therapy. Servagi-Vernat S; Differding S; Hanin FX; Labar D; Bol A; Lee JA; Grégoire V Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1544-52. PubMed ID: 24570097 [TBL] [Abstract][Full Text] [Related]
6. Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. Grosu AL; Souvatzoglou M; Röper B; Dobritz M; Wiedenmann N; Jacob V; Wester HJ; Reischl G; Machulla HJ; Schwaiger M; Molls M; Piert M Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):541-51. PubMed ID: 17869667 [TBL] [Abstract][Full Text] [Related]
7. Correlation between fluorodeoxyglucose hotspots on pretreatment positron emission tomography/CT and preferential sites of local relapse after chemoradiotherapy for head and neck squamous cell carcinoma. Chaput A; Calais J; Robin P; Thureau S; Bourhis D; Modzelewski R; Schick U; Vera P; Salaün PY; Abgral R Head Neck; 2017 Jun; 39(6):1155-1165. PubMed ID: 28263422 [TBL] [Abstract][Full Text] [Related]
8. Assessment of tumor response to chemoradiotherapy and predicting prognosis in patients with head and neck squamous cell carcinoma by PERCIST. Katsuura T; Kitajima K; Fujiwara M; Terada T; Uwa N; Noguchi K; Doi H; Tamaki Y; Yoshida R; Tsuchitani T; Fujita M; Yamakado K Ann Nucl Med; 2018 Aug; 32(7):453-462. PubMed ID: 29858797 [TBL] [Abstract][Full Text] [Related]
9. The role of changes in maximum standardized uptake value of FDG PET-CT for post-treatment surveillance in patients with head and neck squamous cell carcinoma treated with chemoradiotherapy: preliminary findings. Matoba M; Tuji H; Shimode Y; Kondo T; Oota K; Tonami H Br J Radiol; 2017 Mar; 90(1071):20150404. PubMed ID: 28055245 [TBL] [Abstract][Full Text] [Related]
10. Hypoxia-guided adaptive radiation dose escalation in head and neck carcinoma: a planning study. Servagi-Vernat S; Differding S; Sterpin E; Hanin FX; Labar D; Bol A; Lee JA; Grégoire V Acta Oncol; 2015 Jul; 54(7):1008-16. PubMed ID: 25562382 [TBL] [Abstract][Full Text] [Related]
11. Therapy Response Assessment and Patient Outcomes in Head and Neck Squamous Cell Carcinoma: FDG PET Hopkins Criteria Versus Residual Neck Node Size and Morphologic Features. Wray R; Sheikhbahaei S; Marcus C; Zan E; Ferraro R; Rahmim A; Subramaniam RM AJR Am J Roentgenol; 2016 Sep; 207(3):641-7. PubMed ID: 27341273 [TBL] [Abstract][Full Text] [Related]
12. PET-NECK: a multicentre randomised Phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer. Mehanna H; McConkey CC; Rahman JK; Wong WL; Smith AF; Nutting C; Hartley AG; Hall P; Hulme C; Patel DK; Zeidler SV; Robinson M; Sanghera B; Fresco L; Dunn JA Health Technol Assess; 2017 Apr; 21(17):1-122. PubMed ID: 28409743 [TBL] [Abstract][Full Text] [Related]
13. Can "early" and "late"18F-FDG PET-CT be used as prognostic factors for the clinical outcome of patients with locally advanced head and neck cancer treated with radio-chemotherapy? Castaldi P; Rufini V; Bussu F; Miccichè F; Dinapoli N; Autorino R; Lago M; De Corso E; Almadori G; Galli J; Paludetti G; Giordano A; Valentini V Radiother Oncol; 2012 Apr; 103(1):63-8. PubMed ID: 22459579 [TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of clinical and Cho JK; Hyun SH; Choi JY; Choi N; Kim MJ; Lee SH; Baek KH; Jeong HS J Surg Oncol; 2016 Dec; 114(7):888-894. PubMed ID: 27546387 [TBL] [Abstract][Full Text] [Related]
15. Prognostic value of maximum standardized uptake value measured by pretreatment 18F-FDG PET/CT in locally advanced head and neck squamous cell carcinoma. Cacicedo J; Fernandez I; Del Hoyo O; Navarro A; Gomez-Iturriaga A; Pijoan JI; Martinez-Indart L; Escudero J; Gomez-Suarez J; de Zarate RO; Perez JF; Bilbao P; Rades D Clin Transl Oncol; 2017 Nov; 19(11):1337-1349. PubMed ID: 28540535 [TBL] [Abstract][Full Text] [Related]
16. Influence of FAZA PET hypoxia and HPV-status for the outcome of head and neck squamous cell carcinoma (HNSCC) treated with radiotherapy: Long-term results from the DAHANCA 24 trial (NCT01017224). Saksø M; Mortensen LS; Primdahl H; Johansen J; Kallehauge J; Hansen CR; Overgaard J Radiother Oncol; 2020 Oct; 151():126-133. PubMed ID: 32805273 [TBL] [Abstract][Full Text] [Related]
17. Impact of (18)F-FDG PET/CT staging on management and prognostic stratification in head and neck squamous cell carcinoma: A prospective observational study. Ryu IS; Roh JL; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY Eur J Cancer; 2016 Aug; 63():88-96. PubMed ID: 27288873 [TBL] [Abstract][Full Text] [Related]
18. Hypoxia with 18F-fluoroerythronitroimidazole integrated positron emission tomography and computed tomography (18F-FETNIM PET/CT) in locoregionally advanced head and neck cancer: Hypoxia changes during chemoradiotherapy and impact on clinical outcome. Hu M; Xie P; Lee NY; Li M; Ho F; Lian M; Zhao S; Yang G; Fu Z; Zheng J; Ma L; Yu J Medicine (Baltimore); 2019 Oct; 98(40):e17067. PubMed ID: 31577699 [TBL] [Abstract][Full Text] [Related]
19. Predictive and prognostic value of PET/CT imaging post-chemoradiotherapy and clinical decision-making consequences in locally advanced head & neck squamous cell carcinoma: a retrospective study. Kim R; Ock CY; Keam B; Kim TM; Kim JH; Paeng JC; Kwon SK; Hah JH; Kwon TK; Kim DW; Wu HG; Sung MW; Heo DS BMC Cancer; 2016 Feb; 16():116. PubMed ID: 26884055 [TBL] [Abstract][Full Text] [Related]
20. Clinical utility of combined assessments of 4D volumetric perfusion CT, diffusion-weighted MRI and Tsuchiya H; Matoba M; Nishino Y; Ota K; Doai M; Nagata H; Tuji H Radiat Oncol; 2023 Feb; 18(1):24. PubMed ID: 36747228 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]